Non-Muscle Invasive Bladder Cancer Market Set to Sustain Growth Beyond USD 3 Billion Valuation Through 2036

The total market size of Non-Muscle Invasive Bladder Cancer (NMIBC) in the 7MM was valued at approximately USD 3 billion in 2025 and is expected to grow over the forecast period (2026–2036), driven by rising disease prevalence, the launch of high-priced therapies, and a growing number of active companies in the space. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Non-Muscle Invasive Bladder Cancer landscape.

Among the 7MM, the United States accounted for the largest share of the NMIBC market in 2025, representing nearly 65% of the total. The current treatment regimen for the Non-Muscle Invasive Bladder Cancer market includes surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy, though a persistent BCG shortage has pushed physicians toward alternative regimens such as the combination of gemcitabine and docetaxel.

Based on DelveInsight's assessment, the total prevalent cases of NMIBC across the 7MM were nearly 1.56 million in 2025, a figure expected to increase by 2036. Among the 7MM, the US accounted for the highest number of cases in 2025, with around 640,000 prevalent cases. Among EU4 and the UK, total prevalent cases of NMIBC were highest in Italy, while France reported the lowest. Among risk-based categories, the intermediate-risk group accounted for the highest number of cases. In Japan, the 70–89 age group represented approximately 65% of total cases in 2025, while the Ta stage accounted for approximately 64% of stage-specific cases.

DelveInsight's report "Non-muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Non-Muscle Invasive Bladder Cancer landscape. The report delivers detailed insights into the disease, including historical and forecasted epidemiology, treatment practices, emerging drugs, and non-muscle invasive bladder cancer therapeutics market share of individual therapies. The analysis spans the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Non-Muscle Invasive Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Muscle Invasive Bladder Cancer Market Forecast

Some of the key facts of the Non-Muscle Invasive Bladder Cancer Market Report:

• Key Non-Muscle Invasive Bladder Cancer Companies: Merck, Ferring Pharmaceuticals, ImmunityBio, CG Oncology, Pfizer, Fidia Farmaceutici, enGene, UroGen, Theralase, Johnson & Johnson, Roche, AstraZeneca, Protara Therapeutics, and others
• Key Non-Muscle Invasive Bladder Cancer Therapies: KEYTRUDA (pembrolizumab), ADSTILADRIN (nadofaragene firadenovec), ANKTIVA (nogapendekin alfa inbakicept-pmln), CG0070 (cretostimogene grenadenorepvec), Sasanlimab, EG-70 (detalimogene voraplasmid), UGN-102, UGN-103, TAR-200, TAR-210, TECENTRIQ, IMFINZI, Ruvidar, TARA-002, ONCOFID P-B, NanoDoce, Lerapolturev, PADCEV, VAX014, Belzupacap sarotalocan, UGN-301, ZH9, and others
• There are only three FDA-approved drugs for Non-Muscle Invasive Bladder Cancer in the United States: KEYTRUDA (2020), ADSTILADRIN MOA (2022), and ANKTIVA (2024)
• By 2036, among all therapies, cretostimogene grenadenorepvec ± KEYTRUDA is expected to generate the highest revenue in the 7MM
• The Non-Muscle Invasive Bladder Cancer market is expected to surge due to rising prevalence, the launch of high-priced therapies, and the entry of new companies during the forecast period

Non-Muscle Invasive Bladder Cancer Overview

Non-muscle invasive bladder cancer represents a category of bladder cancer where the tumor is confined to the innermost layer of the bladder lining without invading the muscle, accounting for a significant proportion of bladder cancer cases. It is often characterized by superficial tumor growth and typically presents as papillary tumors or carcinoma in situ. Due to its propensity for recurrence and progression, NMIBC requires vigilant management involving transurethral resection of the tumor (TURBT) and subsequent intravesical therapies such as BCG immunotherapy or chemotherapy, along with regular cystoscopic surveillance.

Get a Free sample for the Non-Muscle Invasive Bladder Cancer Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market 

Key Trends in Non-Muscle Invasive Bladder Cancer Treatment Market:

• Persistent BCG shortage reshaping treatment patterns: A long-running BCG shortage has forced physicians toward alternative regimens like gemcitabine and docetaxel, while collaborations such as that between the Serum Institute of India and ImmunityBio aim to strengthen supply and develop an enhanced recombinant BCG.
• Expansion beyond BCG-unresponsive disease: While current approved therapies and much of the pipeline target BCG-unresponsive patients, several late-stage assets (TECENTRIQ, Sasanlimab, IMFINZI, TAR-200) are being evaluated in BCG-naïve, high-risk populations, potentially expanding the addressable patient pool.
• Diversifying mechanisms of action: The emerging pipeline spans checkpoint inhibitors, gene therapy, oncolytic immunotherapy, cell therapy, and drug-device combinations, giving physicians a broader toolkit but also complicating treatment sequencing decisions.
• Innovation in intravesical drug delivery: Devices like TAR-200 and TAR-210 use in-dwelling systems with hyperthermia or electromotive administration to enhance drug uptake, reflecting a shift toward technology-enabled local delivery.
• Shift toward non-surgical management in low-risk disease: Agents like UGN-102 aim to move low-grade, intermediate-risk NMIBC away from recurrent surgical resection toward routine non-surgical treatment.

Non-Muscle Invasive Bladder Cancer Epidemiology

The Non-Muscle Invasive Bladder Cancer epidemiology chapter provides historical and forecasted trends segmented by total prevalent cases, stage-specific cases, grade-specific cases, risk-specific cases, and age-specific cases across the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, from 2022 to 2036.

Non-Muscle Invasive Bladder Cancer Epidemiology Segmentation:

• Total NMIBC Prevalence Cases
• NMIBC Stage-specific Cases
• NMIBC Grade-specific Cases
• NMIBC Risk-specific Cases
• NMIBC Age-specific Cases

Download the report to understand which factors are driving Non-Muscle Invasive Bladder Cancer epidemiology trends @ Non-Muscle Invasive Bladder Cancer Epidemiology Forecast

Recent Developments in the Non-Muscle Invasive Bladder Cancer Treatment Landscape:

• In March 2026, the US FDA acknowledged receipt of a supplemental Biologics License Application (sBLA) in BCG-unresponsive NMIBC with papillary tumors.
• In March 2026, 12-month Phase II interim data reinforced advancement of NDV-01 into a Phase III RESCUE registrational program in second-line BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026.
• In February 2026, Pfizer withdrew its EU marketing authorization application for high-risk NMIBC, as regulatory advice suggested current data was insufficient for approval.
• In November 2025, UroGen discontinued development of UGN-301 (zalifrelimab) after its Phase I profile did not meet internal benchmarks for advancement, despite confirming proof of concept for the RTGel delivery platform.
• In November 2025, the FDA agreed with UroGen's plan to submit an NDA for UGN-103 based on single-arm Phase III UTOPIA trial data, with submission anticipated in the second half of 2026.
• In September 2025, Johnson & Johnson announced FDA approval of INLEXZO (gemcitabine intravesical system) for BCG-unresponsive NMIBC with carcinoma in situ.
• In May 2025, the FDA's ODAC voted 5-4 against approving UGN-102 (mitomycin) for recurrent, low-grade, intermediate-risk NMIBC.
• In May 2025, ImmunityBio received a Refusal to File letter from the FDA for its sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease.

Non-Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to launch in the NMIBC market during the study period, covering market uptake by drug, patient uptake by therapy, and sales of each drug, along with an assessment of the drugs with the most rapid uptake and the reasons behind maximal use. The report also covers pipeline development activities, providing insights into therapeutic candidates across various stages and the key companies developing targeted therapeutics, along with recent collaborations, acquisitions, mergers, licensing and patent details.

Non-Muscle Invasive Bladder Cancer Marketed Therapies and Key Companies

• KEYTRUDA (pembrolizumab): Merck - Anti-PD-1 monoclonal antibody, IV infusion, FDA approved 2020
• ADSTILADRIN MOA (nadofaragene firadenovec-vncg): Ferring Pharmaceuticals/FKD Therapies Oy - AAV gene therapy delivering IFNα2b, intravesical, FDA approved 2022
• ANKTIVA (nogapendekin alfa inbakicept-pmln): ImmunityBio - Recombinant IL-15 receptor superagonist, intravesical, FDA approved 2024

Non-Muscle Invasive Bladder Cancer Emerging Therapies and Key Companies

• CG0070 (cretostimogene grenadenorepvec): CG Oncology - Oncolytic immunotherapy, Phase III
• Sasanlimab (PF-06801591): Pfizer - Anti-PD-1 monoclonal antibody, Phase III
• TECENTRIQ (atezolizumab): Roche - Anti-PD-L1 monoclonal antibody, Phase III
• IMFINZI (durvalumab): AstraZeneca - Anti-PD-L1 monoclonal antibody, Phase III
• UGN-102 / UGN-103 (mitomycin): UroGen Pharma - DNA synthesis inhibitors, Phase III
• TAR-200 / TAR-210: Johnson & Johnson - Intravesical drug-device combinations, Phase III
• ONCOFID P-B: Fidia Farmaceutici - Paclitaxel-hyaluronic acid conjugate, Phase III
• Ruvidar: Theralase Technologies - Photodynamic compound, Phase II
• TARA-002: Protara Therapeutics - Cell therapy, Phase I/II
• EG-70 (detalimogene voraplasmid): enGene - Non-viral plasmid-based gene therapy, Phase I/II

Non-Muscle Invasive Bladder Cancer Drugs Market Insights

BCG remains the leading standard of care in the NMIBC setting. Checkpoint inhibitors (KEYTRUDA) and gene therapy (ADSTILADRIN MOA) are already approved for BCG-unresponsive patients, while the emerging pipeline includes several PD-(L)1 inhibitors in Phase III trials for BCG-naïve patients, including TECENTRIQ, IMFINZI, and Sasanlimab. ANKTIVA plus BCG, the most recently approved therapy, achieved a complete response rate of 62% in NMIBC patients, with 58% and 40% of patients maintaining a duration of response of at least 12 and 24 months, respectively; permanent discontinuation due to adverse reactions occurred in 7% of patients. No oncolytic immunotherapy is yet approved for NMIBC, though CG0070 achieved a complete response in 75.2% of evaluated patients, with a 54% complete response rate at 24 months in the intent-to-treat population, and is being studied in combination with pembrolizumab.

To know more about Non-Muscle Invasive Bladder Cancer companies working in the treatment market, visit @ Non-Muscle Invasive Bladder Cancer Clinical Trials and Therapeutic Assessment

Non-Muscle Invasive Bladder Cancer Market Outlook

NMIBC remains a challenging disease to treat, with high rates of recurrence and progression driving lifelong active surveillance and making bladder cancer among the most expensive cancers to treat from diagnosis to death. Only three drugs are FDA-approved for NMIBC - KEYTRUDA, ADSTILADRIN, and ANKTIVA - all approved in the US only. Real-world data show approximately a quarter of physicians' NMIBC caseload comprises BCG-unresponsive patients, while about a third had not undergone BCG therapy, a challenge exacerbated by the ongoing global BCG scarcity. A robust mid- and late-stage pipeline for both low- and high-risk NMIBC, including CG0070, Sasanlimab, EG-70, UGN-102, UGN-103, Ruvidar, TAR-200, and TAR-210, is expected to launch during the forecast period (2026–2036), reshaping the competitive landscape and treatment paradigm.

Scope of the Non-Muscle Invasive Bladder Cancer Market Report

• Study Period: 2022–2036
• Forecast Period: 2026–2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Non-Muscle Invasive Bladder Cancer Companies: Merck, Ferring Pharmaceuticals, ImmunityBio, CG Oncology, Pfizer, Fidia Farmaceutici, enGene, UroGen, Theralase, Johnson & Johnson, Roche, AstraZeneca, Protara Therapeutics, and others
• Key Non-Muscle Invasive Bladder Cancer Therapies: KEYTRUDA, ADSTILADRIN MOA, ANKTIVA, CG0070, Sasanlimab, EG-70, UGN-102, UGN-103, TAR-200, TAR-210, TECENTRIQ, IMFINZI, Ruvidar, TARA-002, and others
• Non-Muscle Invasive Bladder Cancer Therapeutic Assessment: current marketed and emerging therapies
• Non-Muscle Invasive Bladder Cancer Epidemiology Segmentation: total prevalence, stage-specific, grade-specific, risk-specific, and age-specific cases

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.